Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion, Stanford Team on CTC Test Development

NEW YORK (GenomeWeb) – Fluxion Biosciences said today that it will collaborate with the Stanford University School of Medicine on developing molecular diagnostic tests to identify circulating tumor cells.

The South San Francisco, Calif.-based firm said that Stanford researchers are using its IsoFlux System to "isolate, recover, and analyze rare circulating cancer cells at the molecular level." It expects the collaboration will yield tests that enable the delivery of more effective therapies for cancer patients. The initial focus of the collaboration is prostate and kidney cancer.

Fluxion's IsoFlux can be used in performing a liquid biopsy to collect the CTCs. The cells can then be analyzed by next-generation sequencing for cancer mutational profiling.

"Cancer is a dynamic disease, and the ability to track changes in each patient via a blood sample can allow actionable changes to be detected much earlier," Fluxion Chief Technology Officer Cristian Ionescu-Zanetti said in a statement. "One aim of the collaboration is to identify markers that can help stratify patients requiring more aggressive treatment from those that don't. This is currently a major challenge in the treatment of prostate cancer."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.